Event

The goal of this session about be to discuss and highlight the early clinical study data for repurposing already approved medications for novel therapeutics targeting the pulmonary vasculature and right ventricle in PAH. As we continue to struggle with high costs of PAH-specific therapy and the significant lag in development of novel therapeutics, an attractive method moving forward would be to repurpose already approved medications as we could avoid the long delays for drug approval and proceed directly to clinical trials once there is strong preclinical evidence that they may be effective. This strategy may help us attack PAH pathophysiology through distinct mechanisms than the currently approved therapies do which increases the likelihood of identifying new agents to treat this devastating disease.